Pharmacare Premium Ltd. Zentiva, k.s.

Poland

All drugs from this manufacturer

  • DARUPH

    The medicine is used for the treatment of chronic myeloid leukemia in adults, adolescents, and children (from 1 year of age) and for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults, adolescents, and children (from 1 year of age). It is also used in adults for the lymphoblastic blast crisis of CML if previous treatment has not been effective.

    Dosage form: tablets, film-coated

    Active substance Dosage
    dasatinib 15.8 mg

    ATC: L01XE06

  • The medicine is used in the treatment of chronic myeloid leukemia in adults, adolescents, and children (from 1 year of age) and in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults, adolescents, and children (from 1 year of age). It is also used in adults for the lymphoblastic blast crisis of PBSz, in whom previous treatment was not effective.

    Dosage form: tablets, film-coated

    Active substance Dosage
    dasatinib 39.5 mg

    ATC: L01XE06

  • The medicinal product is used in the treatment of chronic myeloid leukemia in adults, adolescents and children (from 1 year of age) and in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults, adolescents and children (from 1 year of age). It is also used in adults for the blast crisis stage of Ph+ chronic myeloid leukemia in whom previous treatment has not been effective.

    Dosage form: tablets, film-coated

    Active substance Dosage
    dasatinib 55.3 mg

    ATC: L01XE06

  • The medicinal product is used in the treatment of chronic myeloid leukemia in adults, adolescents, and children aged 1 year and older. It is also used in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults, adolescents, and children (from 1 year of age), and in the lymphoblastic blast crisis of chronic myeloid leukemia in adults for whom previous treatment has not been effective.

    Dosage form: tablets, film-coated

    Active substance Dosage
    dasatinib 63.2 mg

    ATC: L01XE06

  • Daruph is used to treat chronic myeloid leukemia in adults, adolescents, and children (from 1 year of age) and to treat acute lymphoblastic leukemia in adults, adolescents, and children (from 1 year of age). It is also used in adults for the lymphoblastic blast crisis of chronic myeloid leukemia in whom previous treatment has not been effective.

    Dosage form: tablets, film-coated

    Active substance Dosage
    dasatinib 79 mg

    ATC: L01XE06

  • The medicine is used in the treatment of chronic myeloid leukemia in adults, adolescents, and children (from 1 year of age) and in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults, adolescents, and children (from 1 year of age). It is also used in the treatment of lymphoblastic blast crisis (PBSz) in adults for whom previous treatment was not effective.

    Dosage form: tablets, film-coated

    Active substance Dosage
    dasatinib 110.6 mg

    ATC: L01XE06